MARKET

DMAC

DMAC

Diamedica Therapeutics Inc
NASDAQ
8.23
-0.24
-2.83%
After Hours: 8.39 +0.16 +1.94% 17:22 12/26 EST
OPEN
8.40
PREV CLOSE
8.47
HIGH
8.43
LOW
8.10
VOLUME
130.65K
TURNOVER
--
52 WEEK HIGH
10.42
52 WEEK LOW
3.190
MARKET CAP
428.60M
P/E (TTM)
-11.4720
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DMAC last week (1215-1219)?
Weekly Report · 6d ago
Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)
TipRanks · 12/20 05:45
After-Hours Biotech Rally: Inspira, MediciNova, DiaMedica Therapeutics Among Gainers
NASDAQ · 12/19 04:27
DiaMedica Therapeutics provides DM199 update following FDA meeting
TipRanks · 12/18 14:16
DiaMedica Advances DM199 Preeclampsia Program After FDA Pre-IND Meeting
TipRanks · 12/18 14:14
DiaMedica Therapeutics Completes Productive In-Person Pre-IND Meeting With FDA For Planned Study Evaluating DM199 In Preeclampsia
Benzinga · 12/18 13:46
DiaMedica Therapeutics Advances DM199 Preeclampsia Clinical Program Following FDA Meeting
Reuters · 12/18 13:45
DIAMEDICA THERAPEUTICS INC - STUDY RESULTS EXPECTED BY Q2 2026
Reuters · 12/18 13:45
More
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.

Webull offers DiaMedica Therapeutics Inc stock information, including NASDAQ: DMAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DMAC stock methods without spending real money on the virtual paper trading platform.